IP Library Patent Application 18087603
Patent Application
App. No. 18/087,603

Methods for Detecting the Presence of a Hypervirulent Clostridium Difficile Strain

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/087,603
Filed
Dec 22, 2022
Art Unit
1681
USPC
506/9
Abstract

The present invention provides a nucleic acid amplification based method for detecting a hypervirulent Clostridium difficile strain in a biological sample. The present invention is based on the use of oligonucleotide primers and probes specific to negative and positive markers in hypervirulent Clostridium difficile genome.

Claims (17)

1 .- 20 . (canceled)

21 . An oligonucleotide primer set comprising a first oligonucleotide comprising or consisting of a nucleotide sequence of at least 10 contiguous nucleotides present in a nucleotide sequence as set forth in SEQ ID NO: 3, a second oligonucleotide comprising or consisting of a nucleotide sequence of at least 10 contiguous nucleotides present in a nucleotide sequence as set forth in SEQ ID NO: 4, wherein the oligonucleotide primer set amplifies a target sequence in the C. difficile hydR gene, and a probe, wherein the probe comprises one or more modified nucleotides and/or a fluorescent label, radiolabel, or phosphorescent label.

22 . The oligonucleotide primer set according to claim 21 , wherein the first oligonucleotide comprises the nucleotide sequence as set forth in SEQ ID NO: 3 and the second oligonucleotide comprises the nucleotide sequence as set forth in SEQ ID NO: 4.

23 . The oligonucleotide primer set according to claim 22 , wherein the first oligonucleotide consists of the nucleotide sequence as set forth in SEQ ID NO: 3 and the second oligonucleotide consists of the nucleotide sequence as set forth in SEQ ID NO: 4.

24 . The oligonucleotide primer set according to claim 21 , further comprising a probe comprising or consisting of a nucleotide sequence of at least 10 contiguous nucleotides as set forth in SEQ ID NO: 7.

25 . The oligonucleotide primer set according to claim 24 , wherein said probe sequence comprises or consists of the nucleotide sequence as set forth in SEQ ID NO: 7.

26 .- 37 . (canceled)

38 . An oligonucleotide probe comprising an oligonucleotide comprising or consisting of a nucleotide sequence of at least 10 contiguous nucleotides present in a nucleotide sequence as set forth in SEQ ID NO: 7, wherein the probe comprises one or more modified nucleotides and/or a fluorescent label, radiolabel, or phosphorescent label.

39 .- 40 . (canceled)

41 . A kit for detecting a hypervirulent Clostridium difficile strain in a biological sample, the kit comprising: the oligonucleotide primer set according to any one of claims 21 - 23 ; and a reagent for performing amplification on a nucleotide acid.

42 . The kit according to claim 41 , wherein the reagent is selected from the group consisting of: DNA polymerase, dNTPs, and a buffer.

43 . An oligonucleotide primer set for generating an amplicon from a C. difficile hydR gene, wherein the primer set comprises a first primer comprising a nucleotide sequence consisting of SEQ ID NO: 3, a second primer wherein the second primer is from 10 to 21 contiguous nucleotides in length, and a probe, wherein the probe comprises one or more modified nucleotides and/or a fluorescent label, radiolabel, or phosphorescent label, and wherein the first and second primers are configured to amplify at least 50 nucleotides of SEQ ID NO: 1.

44 . An oligonucleotide primer set for generating an amplicon from a C. difficile hydR gene, wherein the primer set comprises a first primer comprising a nucleotide sequence consisting of from 10 to 20 contiguous nucleotides, a second primer comprising a nucleotide sequence consisting of SEQ ID NO: 4, and a probe, wherein the probe comprises one or more modified nucleotides and/or a fluorescent label, radiolabel, or phosphorescent label, and wherein the first and second primers are configured to amplify at least 50 nucleotides of SEQ ID NO: 1.

45 . The oligonucleotide primer set according to claim 22 , wherein the probe comprises a nucleotide sequence of at least 10 contiguous nucleotides as set forth in SEQ ID NO: 7.

46 . The oligonucleotide primer set according to claim 23 , wherein the probe comprises a nucleotide sequence of at least 10 contiguous nucleotides as set forth in SEQ ID NO: 7.

47 . The oligonucleotide primer set according to claim 43 , wherein the probe comprises a nucleotide sequence of at least 10 contiguous nucleotides as set forth in SEQ ID NO: 7.

48 . The oligonucleotide primer set according to claim 44 , wherein the probe comprises a nucleotide sequence of at least 10 contiguous nucleotides as set forth in SEQ ID NO: 7.

Assignments (4)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075926/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2025
From: MOBIDIAG OY
To: GEN-PROBE INCORPORATED
Reel/Frame 071007/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2024
From: KIRVESKARI, JUHA; KURKELA, JAAKKO
To: MOBIDIAG LTD
Reel/Frame 066830/0842 →